Compare Cytokinetics Inc (CYTK) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Paychex, Inc. — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Paychex, Inc. trades at $104.29 (market cap $37.19B). The key difference: Paychex, Inc. is far larger — about 4.3× Cytokinetics Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Paychex, Inc. for 56 Days on average.
| CYTK | PAYX | |
|---|---|---|
Market Cap | $8.62B | $37.19B |
Volume | 2,594,626 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $87.26 | $128.59 |
52-Week Low | $54.76 | $85.57 |
Typical Hold Time | 19 Days | 56 Days |
Enterprise Value | $8.72B | $40.87B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and a 47.06% ROE, but valuation metrics like a P/E of 20.15 and P/S of 5.52 suggest a premium. Recent news highlights concerns over dividend sustainability and a 14% stock decline, even as the company reported double-digit earnings growth driven by PEO and insurance segments.
The outlook is mixed: solid fundamentals and a consensus price target of $111.00 imply upside, but bearish technicals and investor skepticism about growth levers like AI pose risks. Key opportunities include consistent dividend payments and market leadership, while risks involve labor market sensitivity and high debt levels following a significant increase in total liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
